BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma
Phase 1 Terminated
96 enrolled
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
Phase 1 Terminated
35 enrolled 10 charts
iinnovate-2
Phase 1 Terminated
15 enrolled 15 charts
A Study of WVT078 in Patients With Multiple Myeloma (MM)
Phase 1 Terminated
56 enrolled
DC15-MM-01
Phase 1 Terminated
4 enrolled
Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
Phase 1 Terminated
6 enrolled
VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)
Phase 1 Terminated
37 enrolled
A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Phase 1 Terminated
174 enrolled
Tasquinimod for the Treatment of Relapsed or Refractory Myeloma
Phase 1 Terminated
30 enrolled
Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant
Phase 1 Terminated
18 enrolled
ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
Phase 1 Terminated
1 enrolled
BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Terminated
24 enrolled
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Terminated
141 enrolled 46 charts
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
Phase 1 Terminated
55 enrolled
CART-38 in Adult AML and MM Patients
Phase 1 Terminated
11 enrolled
A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
Phase 1 Terminated
13 enrolled 10 charts
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 Terminated
5 enrolled
Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma
Phase 1 Terminated
5 enrolled
Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma
Phase 1 Terminated
4 enrolled
Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Terminated
20 enrolled 12 charts
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma
Phase 1 Terminated
183 enrolled
Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma
Phase 1 Terminated
26 enrolled
Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML
Phase 1 Terminated
16 enrolled
A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma
Phase 1 Terminated
26 enrolled
A Safety Study of SEA-BCMA in Patients With Multiple Myeloma
Phase 1 Terminated
83 enrolled 57 charts
T-cell Receptor α/β Depleted Donor Lymphocyte Infusion
Phase 1 Terminated
11 enrolled 11 charts
Descartes-25 in Relapsed/Refractory Multiple Myeloma
Phase 1 Terminated
9 enrolled
Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma
Phase 1 Terminated
16 enrolled
Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia
Phase 1 Terminated
60 enrolled
A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma
Phase 1 Terminated
3 enrolled
QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 Terminated
19 enrolled 22 charts
A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma
Phase 1 Terminated
11 enrolled
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
Phase 1 Terminated
189 enrolled
A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma
Phase 1 Terminated
47 enrolled
Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma
Phase 1 Terminated
4 enrolled
Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1 Terminated
50 enrolled
Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma
Phase 1 Terminated
85 enrolled
Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
Phase 1 Terminated
32 enrolled
Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
Phase 1 Terminated
1 enrolled
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Phase 1 Terminated
249 enrolled 43 charts
Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma
Phase 1 Terminated
23 enrolled
Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma
Phase 1 Terminated
15 enrolled
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Phase 1 Terminated
2 enrolled
A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
Phase 1 Terminated
4 enrolled
Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease
Phase 1 Terminated
1 enrolled
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
Phase 1 Terminated
16 enrolled
BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma
Phase 1 Terminated
19 enrolled
Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma
Phase 1 Terminated
17 enrolled 15 charts
Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)
Phase 1 Terminated
11 enrolled
A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma
Phase 1 Terminated
48 enrolled